Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Change in Cash: 2009-2024

Historic Change in Cash for Madrigal Pharmaceuticals (MDGL) over the last 16 years, with Dec 2024 value amounting to $5.1 million.

  • Madrigal Pharmaceuticals' Change in Cash rose 141.81% to $109.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $63.0 million, marking a year-over-year decrease of 64.12%. This contributed to the annual value of $5.1 million for FY2024, which is 102.20% up from last year.
  • Madrigal Pharmaceuticals' Change in Cash amounted to $5.1 million in FY2024, which was up 102.20% from -$231.6 million recorded in FY2023.
  • Over the past 5 years, Madrigal Pharmaceuticals' Change in Cash peaked at $295.3 million during FY2022, and registered a low of -$231.6 million during FY2023.
  • Moreover, its 3-year median value for Change in Cash was $5.1 million (2024), whereas its average is $22.9 million.
  • Its Change in Cash has fluctuated over the past 5 years, first crashed by 342.71% in 2021, then spiked by 1,764.96% in 2022.
  • Over the past 5 years, Madrigal Pharmaceuticals' Change in Cash (Yearly) stood at $7.3 million in 2020, then plummeted by 342.71% to -$17.7 million in 2021, then spiked by 1,764.96% to $295.3 million in 2022, then slumped by 178.45% to -$231.6 million in 2023, then surged by 102.20% to $5.1 million in 2024.